These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19057167)

  • 1. Clinical trial design issues in mild to moderate Alzheimer disease.
    Knopman DS
    Cogn Behav Neurol; 2008 Dec; 21(4):197-201. PubMed ID: 19057167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials.
    Bernick C; Cummings J; Raman R; Sun X; Aisen P
    Arch Neurol; 2012 Jul; 69(7):901-5. PubMed ID: 22431834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
    Tinklenberg JR; Kraemer HC; Yaffe K; Ross L; Sheikh J; Ashford JW; Yesavage JA; Taylor JL
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):953-60. PubMed ID: 17974866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological assessment in clinical trials of Alzheimer disease.
    Claman DL; Radebaugh TS
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S49-56. PubMed ID: 1781974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.
    Simard M; van Reekum R
    Drugs Aging; 1999 Mar; 14(3):197-230. PubMed ID: 10220105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions.
    Carlsson CM
    J Alzheimers Dis; 2008 Oct; 15(2):327-38. PubMed ID: 18953117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metrifonate for Alzheimer's disease patients.
    Schneider LS
    J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy and safety of the Chinese herbal medicine Di-Tan decoction for treating Alzheimer's disease: protocol for a randomized controlled trial.
    Chua KK; Wong A; Kwan PW; Song JX; Chen LL; Chan AL; Lu JH; Mok V; Li M
    Trials; 2015 Apr; 16():199. PubMed ID: 25925312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.
    Broich K
    Int Psychogeriatr; 2007 Jun; 19(3):509-24. PubMed ID: 17433121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verbal repetition in people with mild-to-moderate Alzheimer Disease: a descriptive analysis from the VISTA clinical trial.
    Cook C; Fay S; Rockwood K
    Alzheimer Dis Assoc Disord; 2009; 23(2):146-51. PubMed ID: 19474572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
    Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
    Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
    Gustavsson A; Cattelin F; Jönsson L
    Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Alzheimer's disease: hopes and reality.
    Gauthier S; Gauthier L; Bouchard R; Quirion R; Sultan S
    Can J Neurol Sci; 1991 Aug; 18(3 Suppl):439-41. PubMed ID: 1933695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment issues in clinical trials of tetrahydroaminoacridine and studies to alter decline in Alzheimer disease.
    Thal LJ
    Alzheimer Dis Assoc Disord; 1991; 5 Suppl 1():S37-9. PubMed ID: 1781972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.